It is an honor to be among these highly accomplished women #leaders. Looking forward to this in-person event. #longwoodhealthcareleaders #biotech

Had a very #productive #strategicplanning #offsite session with my team! Covered many aspects including #unified vision, business #alignment , #priorities and #goals. #biotech

Looking forward to the in-person discussion with my esteemed panelists and moderator at the #longwoodhealthcareleaders Spring 2023 MIT event next week. Longwood Healthcare Leaders #biotech

See you at #BIO2023 where I will be #presenting Novasenta's progress and attending #partneringmeetings.

cancer cell lines and mice are critical models for studying cancer. 7 data resources for cancer cell lines and mouse models👇 🧵

Probably the best ADC review I came across, so much valuable information + great figures on targets, linkers and payloads! tandfonline.com/doi/full/10.10…

🧵JUST RELEASED: Part 2 of the Annual Report to the Nation on the Status of Cancer shows the impact of the COVID-19 pandemic on the number of newly diagnosed cancer cases in the U.S. go.nih.gov/P9ott5W #CancerAnnualReport #NCIFuture

So true….

As a member of CLP Executive Advisory Board, I’d like to invite you to consider a gift to the Institute on this #GivingTuesday. A key CLP initiative is to understand #ALS and #Alzheimer's through proteoform research to support new therapeutics discovery & development

Excited to present the Novasenta story at #PMWC24

Was great to be a part of this conference and meet new people #PMWC24 #biotech

Only tweet for #ASCO24 The response rate for Gem-Abraxane in #PancreaticCancer was 48% in the Phase1b/2 & less than half (23%) in the Phase 3 (real world it’s more like 30%). Bottom line - early phase trials are carefully selected patients for many reasons. Healthy skepticism is

The #RewritingCancer series explores the most exciting progress in cancer research and treatments. Check out the video featuring our story which was produced by BBC StoryWorks Commercial Productions: bit.ly/4dfD8Fq

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

🎉 Big congrats to CLP Director Dr. Neil Kelleher on receiving the 2025 #StreckAward! His pioneering work on #proteoforms is reshaping how we understand human biology and disease. Learn more about the Human Proteoform Project → bit.ly/43LtyaI #Proteomics Neil Kelleher

Learn how targeting T-cells and the tumor microenvironment can help overcome T-cell exhaustion in multiple myeloma with Dr. Samir Parekh at #IMS25. Strengthening your immune system may improve treatment response and overall outcomes. #mmsm #ims25 youtu.be/nbwIBnPdM6U?si…

Exciting to see effectiveness of #S100A8A9 antibodies developed by us in reversing resistance to bispecific therapies and CARTs in myeloma. Antibodies being developed for clinical use by Roshon Therapeutics.